Advanced search    

Search: authors:"Jean-Jacques Body"

16 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Hypercalcaemia and hypocalcaemia: finding the balance

malignancy; Denosumab; Bisphosphonates - * Jean-Jacques Body Daniela Niepel Giuseppe Tonini Treatment of hypercalcaemia of malignancy Inhibitors of bone resorption, first the bisphosphonates and, later

An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries

funded by Amgen (Europe) GmbH. Jean-Jacques Body has received speaker and consulting fees from Amgen; Francesca Gatta is an employee of Amgen; Erwin De Cock and Persefoni Kritikou were employees of UBC

Increased fracture rate in women with breast cancer: a review of the hidden risk

Background Women with breast cancer, particularly individuals diagnosed at a relatively early age, have an increased incidence of fractures. Fractures can have serious clinical consequences including the need for major surgery, increased morbidity and mortality, increased cost of disease management, and reduced quality of life for patients. The primary cause of the increased ...

Effects of Dairy Products Consumption on Health: Benefits and Beliefs—A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

Dairy products provide a package of essential nutrients that is difficult to obtain in low-dairy or dairy-free diets, and for many people it is not possible to achieve recommended daily calcium intakes with a dairy-free diet. Despite the established benefits for bone health, some people avoid dairy in their diet due to beliefs that dairy may be detrimental to health, especially in ...

Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases

from Amgen; speaker honoraria and consultant fee from GSK and Novartis; speaker honoraria, consultant fee, and research grant from Roche; and speaker honoraria from Bayer. Jean-Jacques Body received

Health resource utilization associated with skeletal-related events: results from a retrospective European study

Background Bone complications, also known as skeletal-related events (SREs), are common in patients with bone metastases secondary to advanced cancers. Objective To provide a detailed estimate of the health resource utilization (HRU) burden associated with SREs across eight European countries. Methods Eligible patients from centers in Austria, the Czech Republic, Finland, Greece, ...

Patients’ preferences for bone metastases treatments in France, Germany and the United Kingdom

- choice experiment survey of ten questions, choosing between pairs of hypothetical Roger von Moos and Jean-Jacques Body shared last authorship. - Bone is one of the most common sites for metastatic spread

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

as a consultant for Amgen Inc. Jean-Jacques Body worked as a consultant for Amgen Inc. and Bayer. Janet E. Brown worked as a consultant for Amgen Inc., Novartis, and Bristol Myers Squibb and received

Health state utilities for skeletal-related events secondary to bone metastases

Brazier and Jean-Jacques Body received funding from Amgen for time spent contributing to this research. The input of all authors into the conceptualization and interpretation of this study represented their

Health Technology Assessment in Osteoporosis

We review the various aspects of health technology assessment in osteoporosis, including epidemiology and burden of disease, and assessment of the cost-effectiveness of recent advances in the treatment of osteoporosis and the prevention of fracture, in the context of the allocation of health-care resources by decision makers in osteoporosis. This article was prepared on the basis ...

The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts

Mehdi Najar Martine Piccart Ghanem Ghanem 0 Jean-Jacques Body Fabrice Journé 0 0 Laboratoire d'Oncologie et de Chirurgie Expérimentale, Institut Jules Bordet, Université Libre de Bruxelles , Brussels

Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells

Introduction Bisphosphonates have become standard therapy for the treatment of skeletal complications related to breast cancer. Although their therapeutic effects mainly result from an inhibition of osteoclastic bone resorption, in vitro data indicate that they also act directly on breast cancer cells, inhibiting proliferation and inducing apoptosis. Methods The present study ...

Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines

Introduction Bisphosphonates are inhibitors of osteoclast-mediated tumor-stimulated osteolysis, and they have become standard therapy for the management of bone metastases from breast cancer. These drugs can also directly induce growth inhibition and apoptosis of osteotropic cancer cells, including estrogen receptor-positive (ER+) breast cancer cells. Methods We examined the ...

Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments

the CTX immunoassays. Per Qvist and Claus Christiansen own shares in Nordic Bioscience A/S. Jean-Jacques Body and Nina Lyubimova have no competing interests.